Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: On the distribution side, you mentioned specific lines like short-term medical and employer stop loss were weaker. Do you expect this trend to persist, and how should we think about the prospects for these lines? A: Claude LeBlanc, President and CEO, explained that the employer stop loss sector has seen widespread deterioration, which is considered a macro trend. However, there could be stabilization in the near future. For short-term medical, challenges were noted under the past administration, but there is optimism for a return to steady state with the new administration. Overall, growth is significant across various areas in A&H, with ESL being the biggest challenge.
Q: Regarding the specialty P&C side, the combined ratio showed continued progress. Is this sustainable, or are there temporary factors at play? A: David Trick, CFO, stated that the focus is on profitability rather than just growth. The effective loss ratios are in the mid-60s, aligning with long-term goals for Everspan. While there will be variability due to market developments, the quarter's performance is consistent with long-term objectives.
Q: Can you provide more details on the impact of the Beat acquisition on your financials? A: David Trick, CFO, noted that the acquisition of Beat Capital significantly contributed to revenue growth, with premiums placed growing 309% and total revenue increasing by 257% compared to the previous year. The acquisition also led to increased intangible amortization and interest expenses, impacting adjusted EBITDA.
Q: How is the sale of the legacy financial guarantee business progressing, and what are the expected benefits? A: Claude LeBlanc, President and CEO, mentioned that the sale to Oaktree for $420 million is nearing completion, pending regulatory approval. This sale allows Ambac to accelerate the scaling of its specialty P&C business and focus on future growth, with expectations of strong organic growth and significant adjusted EBITDA by 2028.
Q: What are the key factors driving the growth in your specialty commercial auto business? A: Claude LeBlanc, President and CEO, highlighted that the specialty commercial auto business performed particularly well, offsetting headwinds in other areas. The growth is supported by rate increases in US casualty lines and a favorable market environment for E&S commercial insurance.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.